Series A · Medtech & Devices · Geneva, Switzerland · Founded 2018 · 1–10 employees
EBAMed develops innovative solutions for non-invasive and painless treatment of heart arrhythmias using proton therapy technology. The company has created CardioKit, a medical device that enables real-time cardiac motion monitoring and synchronization for radiation therapy systems. EBAMed raised EUR 16 million in Series A funding, with the most recent EUR 1.6 million closure in January 2025 bringing total Series A to EUR 16 million. The company targets the 50 million people worldwide affected by cardiac arrhythmias, offering an alternative to traditional invasive procedures.
No open roles listed right now.